Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis

• Autors principals: A. R. Tellegen (Autor), I. Rudnik-Jansen (Autor), B. Pouran (Autor), H. M. de Visser (Autor), H. H. Weinans (Autor), R. E. Thomas (Autor), M. J. L. Kik (Autor), G. C. M. Grinwis (Autor), J. C. Thies (Autor), N. Woike (Autor), G. Mihov (Autor), P. J. Emans (Autor), B. P. Meij (Autor), L. B. Creemers (Autor), M. A. Tryfonidou (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Major hallmarks of osteoarthritis (OA) are cartilage degeneration, inflammation and osteophyte formation. COX-2 inhibitors counteract inflammation-related pain, but their prolonged oral use entails the risk for side effects. Local and prolonged administration in biocompatible and degradable drug del...